These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 25335710)

  • 21. [Methods of preventing phlebitis induced by infusion of fosaprepitant].
    Kohno E; Kanematsu S; Okazaki S; Ogata M; Kanemitsu M; Yamashita H; Syuntou K; Sekita M; Nishioka R; Yoshida H
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):323-6. PubMed ID: 25812501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors].
    Kitada M; Sawaragi I
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):87-91. PubMed ID: 8546476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Assessment of nausea and vomiting during FEC regimen for breast cancer after the novel antiemetic agent - introduction using MASCC antiemesis tool].
    Oshiro C; Kamigaki S; Nakamura Y; Arai T; Kanai Y; Fujino M; Fujii C; Hamaguchi Y; Iseki C; Hachino Y; Furukawa H
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):241-4. PubMed ID: 22333635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
    N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
    Taguchi T; Tsukamoto F; Watanabe T; Yoneda K; Takamura Y; Hojo S; Shiba E; Noguchi S
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1163-70. PubMed ID: 10431583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer.
    Abali H; Oyan B; Guler N
    Chemotherapy; 2005 Aug; 51(5):280-5. PubMed ID: 16103667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V; Wan HS; Chan A
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
    Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
    J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
    Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
    Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting.
    Ho CL; Su WC; Hsieh RK; Lin ZZ; Chao TY
    Jpn J Clin Oncol; 2010 Apr; 40(4):294-301. PubMed ID: 20026457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.
    Italian Group for Antiemetic Research
    N Engl J Med; 1995 Jan; 332(1):1-5. PubMed ID: 7990859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
    Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
    Bodge M; Shillingburg A; Paul S; Biondo L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1111-3. PubMed ID: 24357337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
    Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
    Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.